Indaptus Therapeutics, Inc.

NASDAQ: INDP · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001857044Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 31DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ return on equity, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$20.8M

Employees

as of 2026-08-23

Market cap

$146.1M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$20.8M-$20.8M2025

Operating income-$19.8M-$19.8M2025

Total assets$9.3M$9.3M2025

Liabilities$3.4M$3.4M2024

Equity$3.2M$3.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Indaptus Therapeutics, Inc.’s financial profile?

Indaptus Therapeutics, Inc. earned -$20.8M in FY2025 net income.

Peers · Healthcare

Tenaya Therapeutics, Inc.——Armata Pharmaceuticals, Inc.——Canton Strategic Holdings Inc——NervGen Pharma Corp. Common stock——Milestone Pharmaceuticals Inc.——Polaryx Therapeutics, Inc. Common Stock——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOJunyi Dai

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: INDP

Employees5

IPO date2015-08-04

Latest filings

10-Q2026-08-13 8-K2026-08-13 DEF 14A2026-07-16 8-K2026-06-24 8-K2026-06-05 8-K2026-05-15 10-Q2026-05-15 8-K2026-04-23

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.